Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2005 1
2009 1
2010 2
2011 1
2012 2
2013 2
2014 5
2015 4
2016 1
2018 1
2019 2
2021 1
2022 1
2024 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

28 results

Results by year

Filters applied: . Clear all
Page 1
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.
Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, Spicka I, Hungria V, Munder M, Mateos MV, Mark TM, Qi M, Schecter J, Amin H, Qin X, Deraedt W, Ahmadi T, Spencer A, Sonneveld P; CASTOR Investigators. Palumbo A, et al. N Engl J Med. 2016 Aug 25;375(8):754-66. doi: 10.1056/NEJMoa1606038. N Engl J Med. 2016. PMID: 27557302 Free article. Clinical Trial.
Doxorubicin Exposure and Breast Cancer Risk in Survivors of Adolescent and Adult Hodgkin Lymphoma.
Neppelenbroek SIM, Geurts YM, Aleman BMP, Lugtenburg PJ, Rademakers SE, de Weijer RJ, Schippers MGA, Ta BDP, Plattel WJ, Zijlstra JM, van der Maazen RWM, Nijziel MR, Ong F, Schimmel EC, Posthuma EFM, Kersten MJ, Böhmer LH, Muller K, Koene HR, Te Boome LCJ, Bilgin YM, de Jongh E, Janus CPM, van Leeuwen FE, Schaapveld M. Neppelenbroek SIM, et al. Among authors: te boome lcj. J Clin Oncol. 2024 Jun 1;42(16):1903-1913. doi: 10.1200/JCO.23.01386. Epub 2024 Feb 15. J Clin Oncol. 2024. PMID: 38359378 Free PMC article.
Current insights into ocular graft-versus-host disease.
Riemens A, te Boome L, Imhof S, Kuball J, Rothova A. Riemens A, et al. Among authors: te boome l. Curr Opin Ophthalmol. 2010 Nov;21(6):485-94. doi: 10.1097/ICU.0b013e32833eab64. Curr Opin Ophthalmol. 2010. PMID: 20729735 Review.
Treatment-specific risk of subsequent malignant neoplasms in five-year survivors of diffuse large B-cell lymphoma.
Geurts YM, Neppelenbroek SIM, Aleman BMP, Janus CPM, Krol ADG, van Spronsen DJ, Plattel WJ, Roesink JM, Verschueren KMS, Zijlstra JM, Koene HR, Nijziel MR, Schimmel EC, de Jongh E, Ong F, Te Boome LCJ, van Rijn RS, Böhmer LH, Ta BDP, Visser HPJ, Posthuma EFM, Bilgin YM, Muller K, van Kampen D, So-Osman C, Vermaat JSP, de Weijer RJ, Kersten MJ, van Leeuwen FE, Schaapveld M. Geurts YM, et al. Among authors: te boome lcj. ESMO Open. 2024 Feb;9(2):102248. doi: 10.1016/j.esmoop.2024.102248. Epub 2024 Feb 12. ESMO Open. 2024. PMID: 38350338 Free PMC article.
Clinical characteristics and survival outcomes of patients with primary central nervous system lymphoma treated with high-dose methotrexate-based polychemotherapy and consolidation therapies.
de Groot FA, Dekker TJA, Doorduijn JK, Böhringer S, Brink M, de Groen RAL, de Haan LM, Woei-A-Jin FJSH, Noordenbos T, Sijs-Szabo A, Oudshoorn MA, Lam KH, Diepstra A, Te Boome LCJ, Terpstra V, Bohmer LH, Nicolae A, Posthuma EFM, Koens L, Durian MF, Stavast J, van der Poel MWM, Hamid MA, Stevens WBC, van Rooij SLM, Oostvogels RS, Mühlebner A, Neelis KJ, van den Brand M, Tousseyn T, Dierickx D, de Weerdt O, Beeker A, Jansen PM, Kersten MJ, Zijlstra JM, Chamuleau MED, Veelken H, Bromberg JCE, Nijland M, Vermaat JSP. de Groot FA, et al. Among authors: te boome lcj. Eur J Cancer. 2024 Dec;213:115068. doi: 10.1016/j.ejca.2024.115068. Epub 2024 Oct 13. Eur J Cancer. 2024. PMID: 39427440 Free article.
R-CEOP as first-line treatment for anthracycline-ineligible patients with diffuse large B-cell lymphoma.
Al-Sarayfi D, Meeuwes FO, Durmaz M, Issa DE, Brouwer RE, Beeker A, van Rhenen A, Mutsaers PGNJ, Böhmer LH, van der Poel MWM, Te Boome L, van Meerten T, Chamuleau MED, Zijlstra JM, Brink M, Nijland M. Al-Sarayfi D, et al. Among authors: te boome l. Blood Cancer J. 2022 Sep 2;12(9):125. doi: 10.1038/s41408-022-00723-4. Blood Cancer J. 2022. PMID: 36055987 Free PMC article. No abstract available.
Impact of comorbidity on health-related quality of life in newly diagnosed patients with lymphoma or multiple myeloma: results from the PROFILES-registry.
Ekels A, van de Poll-Franse LV, Issa DE, Hoogendoorn M, Nijziel MR, Koster A, de Jong CN, Achouiti A, Thielen N, Tick LW, Te Boome LCJ, Bohmer LH, Tiren-Verbeet NL, Veldhuis GJ, de Boer F, van der Klift M, Posthuma EFM, Oerlemans S. Ekels A, et al. Among authors: te boome lcj. Ann Hematol. 2024 Sep 16. doi: 10.1007/s00277-024-06006-1. Online ahead of print. Ann Hematol. 2024. PMID: 39279019
Frequent mutated B2M, EZH2, IRF8, and TNFRSF14 in primary bone diffuse large B-cell lymphoma reflect a GCB phenotype.
de Groen RAL, van Eijk R, Böhringer S, van Wezel T, Raghoo R, Ruano D, Jansen PM, Briaire-de Bruijn I, de Groot FA, Kleiverda K, Te Boome L, Terpstra V, Levenga H, Nicolae A, Posthuma EFM, Focke-Snieders I, Hardi L, den Hartog WCE, Bohmer LH, Hogendoorn PCW, van den Berg A, Diepstra A, Nijland M, Lugtenburg PJ, Kersten MJ, Pals ST, Veelken H, Bovée JVMG, Cleven AHG, Vermaat JSP. de Groen RAL, et al. Among authors: te boome l. Blood Adv. 2021 Oct 12;5(19):3760-3775. doi: 10.1182/bloodadvances.2021005215. Blood Adv. 2021. PMID: 34478526 Free PMC article.
28 results